

Cipla introduces HUENA® – India's first non-antibiotic drug for recurring urinary tract infections

Methenamine Hippurate is globally recognized and utilized in over 30 countries including the United States, Europe and Chile

Mumbai, September 05, 2025: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") today announced the launch of Methenamine Hippurate, a non-antibiotic treatment for patients suffering from recurrent urinary tract infections (UTIs), under the brand name HUENA. This marks a significant step forward for Cipla in the fight against Anti-Microbial Resistance (AMR) and reinforces its commitment to anti-microbial stewardship, as it becomes the first to introduce this treatment in India.

UTIs are the second most common reason for antibiotic use in India, with infection cases doubling over the last 30 years. Women are more susceptible to UTIs, which account for 15% of overall antibiotic prescriptions. Methenamine Hippurate offers an effective, non-antibiotic alternative for preventing UTIs by targeting bacteria in the bladder and urinary tract. Studies show it is as effective as long-term, low-dose antibiotic therapy for UTI prevention, with lower costs and no risk of antibiotic resistance.

Commenting on this milestone, Achin Gupta, Global Chief Operating Officer, Cipla, said: "The launch of HUENA reflects our strong commitment to antimicrobial stewardship and addressing the growing challenge of AMR. We believe this innovation will notably improve patient outcomes, while reducing reliance on antibiotics, further contributing to a healthier future for all."

Commenting on the launch, Dr. Jaideep Gogtay, Global Chief Medical Officer, Cipla, said: "At Cipla, we recognise the urgent need for innovative solutions to combat the growing burden of AMR. This groundbreaking launch provides patients with a non-antibiotic drug that will help prevent urinary tract infections without contributing to antimicrobial resistance."

About Cipla

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 74+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Mar'25), 2nd largest in the pharma prescription market in South Africa (IQVIA MAT Feb'25), and 4th largest by prescription for Generic inhalation products in the US Gx (IQVIA TRx MAT Mar'25). For almost nine decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility, and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

Corporate Communications

Heena Kanal

E-Mail: CorpComm@cipla.com

Investor Relations

Diksha Maheshwari

E-Mail: Investor.Relations@cipla.com